Congress-ISPOR
Glasgow-uk-mobile

Primary Hyperoxaluria Type 1 (PH1)

European Renal Association (ERA) 2026

Congress Details

calanderJune 3-6, 2026

locationGlasgow, Scotland

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Agenda

04 June, 2026

ERA-2026-NC-Outcomes-ILLUM-A_eposter-talk_Final
icon Presentation Type
Oral presentation
time icon Time
8:27 AM - 8:33 AM BST
location icon Location
Focused Oral Room 2
icon Title
Long-Term Lumasiran Treatment and Nephrocalcinosis Outcomes in Primary Hyperoxaluria Type 1: A Post Hoc Analysis of ILLUMINATE-A
mic Presenter

Wesley Hayes
Zurich Childrens Hospital,
Zurich, Switzerland

05 June, 2026

Coming soon
icon Presentation Type
Oral presentation
time icon Time
4:48 PM - 5:00 PM BST
location icon Location
Forth Room
icon Title
Final 60-Month Results of ILLUMINATE-C Evaluating Lumasiran Treatment of Primary Hyperoxaluria Type 1 in Patients With Advanced Kidney Disease
mic Presenter

Wesley Hayes
Zurich Childrens Hospital,
Zurich, Switzerland

Coming soon
icon Presentation Type
Oral presentation
time icon Time
5:45 PM - 5:51 PM BST
location icon Location
Focused Oral Room 6
icon Title
Impact of Baseline Urinary Oxalate on Response to Lumasiran Treatment in the ILLUMINATE-A Study of Primary Hyperoxaluria Type 1​
mic Presenter

Yaacov Frishberg
Shaare Zedek Medical Center Jerusalem, Israel